PUBLISHER: QYResearch | PRODUCT CODE: 1064991
PUBLISHER: QYResearch | PRODUCT CODE: 1064991
Due to the COVID-19 pandemic, the global Cerebral Embolic Protection Devices for TAVI market size was value at US$ 52.23 million in 2021 and is forecast to be a readjusted size of US$ 257.67 million by 2028 with a CAGR of 25.89% during the forecast period 2022-2028.
The global main manufacturers of Cerebral Embolic Protection Devices for TAVI include Venus Medtech (Keystone Heart) and Boston Scientific (Claret Medical) In 2021, the global two largest players have a share approximately 100% in terms of revenue.
The North America Cerebral Embolic Protection Devices for TAVI market size was US$ 21.73 million in 2021. The proportion of the China was 0% in 2021 and it is predicted that the share will reach 2.87% in 2028, trailing a CAGR of 27.44% through the2023-2028. As for the Europe Cerebral Embolic Protection Devices for TAVI landscape, Germany is projected to reach US$ 59.22 million by 2028.
Fully considering the economic change by the COVID-19, Total Artery Coverage accounting for 5.88% of the Cerebral Embolic Protection Devices for TAVI global market in 2021, is projected to value US$ 42.8 million by 2028, growing at a revised 47.44% CAGR from 2022 to 2028. While Hospital segment is altered to an 25.63% CAGR throughout this forecast period and will hold a share about 82.08% in 2028.
The global Cerebral Embolic Protection Devices for TAVI market is segmented by region (country), company, by Type, and by Application. Players, stakeholders, and other participants in the global Cerebral Embolic Protection Devices for TAVI market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type, and by Application for the period 2017-2028.